Organon & Co. 8-K

What Happened Organon & Co. (OGN) filed an 8-K on July 17, 2026 disclosing that a shareholder sued on July 6, 2026 in Mercer County, NJ, alleging the company’s definitive proxy for the planned merger with Sun Pharmaceutical Holdings USA, Inc. omitted material information. The plaintiff has moved (July 13, 2026) to preliminarily enjoin the July 23, 2026 special stockholder meeting. Organon says the claims are without merit, denies any liability, but will voluntarily supplement the definitive proxy statement to avoid potential delays or costs associated with the litigation. The original Merger Agreement among Organon, Sun Pharma USA and a Sun Pharma subsidiary was entered April 26, 2026; Organon filed the definitive proxy on June 17, 2026.

Key Details

• Complaint filed July 6, 2026 (Richard Delman v. Organon et al.); injunction motion filed July 13, 2026 and not yet decided.
• Organon will supplement the definitive proxy statement while expressly denying the legal necessity or materiality of the added disclosures.
• Organon disclosed preliminary estimated synergies of approximately $700 million across commercial, procurement, R&D and corporate functions.
• Updated financials: 2026E revenue $6,252 million and Adjusted EBITDA $1,894 million; net debt as of March 31, 2026 was $7,530 million; fully diluted shares ~284.9 million.

Why It Matters Litigation over the proxy could delay or disrupt the scheduled shareholder vote on the Sun Pharma merger and create added legal costs or uncertainty. Organon’s voluntary supplemental disclosures aim to reduce that risk and provide investors with additional detail — including a $700M preliminary synergy estimate and near-term financial projections — but the company maintains the lawsuit’s claims are meritless. Investors should monitor the court’s ruling on the injunction motion and any further updates to the proxy or merger timing.